Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

mergers and acquisition
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
Thermo Fisher to Buy Patheon for $5.2 Billion
Thermo Fisher to Buy Patheon for $5.2 Billion
Aggie Mika | May 16, 2017
The scientific supply giant seeks to expand into biopharma development and manufacturing.  
Monsanto and Bayer Announce Approval of Massive Merger
Monsanto and Bayer Announce Approval of Massive Merger
Bob Grant | Dec 13, 2016
On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.
Novartis Buys US Drugmaker for Up To $665 Million
Novartis Buys US Drugmaker for Up To $665 Million
Tracy Vence | Nov 22, 2016
The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.
Allergan’s Buying Spree Rolls On
Allergan’s Buying Spree Rolls On
Bob Grant | Sep 21, 2016
The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.
Allergan Set to Buy Vitae
Allergan Set to Buy Vitae
Bob Grant | Sep 16, 2016
The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.
Bayer Looks to Buy Monsanto
Bayer Looks to Buy Monsanto
Bob Grant | Sep 14, 2016
The US agribusiness behemoth agreed to a $57 billion buyout offer from the European pharmaceutical giant.